Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway

BACKGROUND: To explore the effect and mechanism of pirfenidone in inhibiting pulmonary fibrosis in connective tissue disease-associated interstitial lung disease (CTD-ILD). METHODS: From 2018 to 2020, 50 CTD-ILD patients were enrolled in the clinical study. Based on whether pirfenidone was used duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Yanhua, Liu, Jing, Xu, Huaheng, Li, Yanxia, Tao, Ran, Zhang, Zongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264050/
https://www.ncbi.nlm.nih.gov/pubmed/35813760
http://dx.doi.org/10.21037/jtd-22-41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264050/
https://www.ncbi.nlm.nih.gov/pubmed/35813760
http://dx.doi.org/10.21037/jtd-22-41

Ejemplares similares